NCT07435467 Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)
| NCT ID | NCT07435467 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituto Nazionale di Ricovero e Cura per Anziani |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-04-09 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2025-04-09 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.
Eligibility Criteria
GROUP 1: Patients hospitalized for acute neurological disorders Inclusion criteria: * Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis Exclusion criteria: * no informed consent GROUP 2: Patients hospitalized for non-neurological diseases with dementia Inclusion criteria: * inpatients with diagnosis of major neurocognitive disorder according to DSM-5 criteria (2013) Exclusion criteria: * Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis * no informed consent GROUP 3: Patients hospitalized for non-neurological diseases without dementia Inclusion criteria: * inpatients with non-neurological diseases Exclusion criteria: * inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis * diagnosis of dementia * no informed consent
Contact & Investigator
Fabiola Olivieri, Professor
STUDY CHAIR
IRCCS INRCA, Ancona, Italy
Frequently Asked Questions
Who can join the NCT07435467 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07435467 currently recruiting?
Yes, NCT07435467 is actively recruiting participants. Contact the research team at a.bonfigli@inrca.it for enrollment information.
Where is the NCT07435467 trial being conducted?
This trial is being conducted at Ancona, Italy, Fermo, Italy, Messina, Italy.
Who is sponsoring the NCT07435467 clinical trial?
NCT07435467 is sponsored by Istituto Nazionale di Ricovero e Cura per Anziani. The principal investigator is Fabiola Olivieri, Professor at IRCCS INRCA, Ancona, Italy. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.